13.61
-0.08(-0.58%)
Currency In USD
| Previous Close | 13.69 |
| Open | 13.55 |
| Day High | 13.63 |
| Day Low | 13.38 |
| 52-Week High | 19.58 |
| 52-Week Low | 4.88 |
| Volume | 14,448 |
| Average Volume | 181,555 |
| Market Cap | 296.33M |
| PE | -5.38 |
| EPS | -2.53 |
| Moving Average 50 Days | 11.81 |
| Moving Average 200 Days | 11.1 |
| Change | -0.08 |
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
GlobeNewswire Inc.
Dec 10, 2025 9:05 PM GMT
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients who have completed HERO trial
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
GlobeNewswire Inc.
Nov 25, 2025 9:05 PM GMT
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire Inc.
Nov 11, 2025 9:05 PM GMT
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the